Patient (n = 32) demographics, disease, and prior treatment characteristics
| Demographics . | Value . |
|---|---|
| Sex, female, no. (%) | 13 (41) |
| Median age, y (range) | 61 (35-83) |
| Prior lines of therapy, median (range) | 2 (1-7) |
| Corticosteroids | 100 (%) |
| Alkylating agent | 81 |
| Lenalidomide | 63 |
| Bortezomib | 59 |
| Autologous stem cell transplant | 59 |
| Thalidomide | 44 |
| Anthracycline | 38 |
| Other | 9 |
| Median time, diagnosis to enrollment, y, (range) | 2.2 (0.7-11) |
| Median time, last therapy to enrollment, mo, (range) | 6.5 (1.2-32.9) |
| International Staging System stage, % | |
| I | 81 |
| II | 6 |
| III | 13 |
| M-protein, % | |
| IgG | 59 |
| IgA | 28 |
| Light chain | 13 |
| Cytogenetics, % | |
| Standard risk | 72 |
| High risk | 28 |
| Demographics . | Value . |
|---|---|
| Sex, female, no. (%) | 13 (41) |
| Median age, y (range) | 61 (35-83) |
| Prior lines of therapy, median (range) | 2 (1-7) |
| Corticosteroids | 100 (%) |
| Alkylating agent | 81 |
| Lenalidomide | 63 |
| Bortezomib | 59 |
| Autologous stem cell transplant | 59 |
| Thalidomide | 44 |
| Anthracycline | 38 |
| Other | 9 |
| Median time, diagnosis to enrollment, y, (range) | 2.2 (0.7-11) |
| Median time, last therapy to enrollment, mo, (range) | 6.5 (1.2-32.9) |
| International Staging System stage, % | |
| I | 81 |
| II | 6 |
| III | 13 |
| M-protein, % | |
| IgG | 59 |
| IgA | 28 |
| Light chain | 13 |
| Cytogenetics, % | |
| Standard risk | 72 |
| High risk | 28 |